This paper investigates the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. The effect of the vintage of prescription drugs (and other variables) on the life expectancy and ageadjusted mortality rates of residents of Germany is examined, using longitudinal, annual, state-level data during the period 2001-7. The estimates imply that about one-third of the 1.4-year increase in German life expectancy during the period 2001-7 was due to the replacement of older drugs by newer drugs. The effect of the vintage of chemotherapy treatments on age-adjusted cancer mortality rates of residents of France is also investigated, using longitudinal, annual, cancer-site-level data during the period 2002-6. The estimates imply that chemotherapy innovation accounted for at least one-sixth of the decline in French cancer mortality rates, and may have accounted for as much as half of the decline.
worth over $1.2 million per person for both men and women. Between 1970 and 2000 increased longevity added about $3.2 trillion per year to national wealth, an uncounted value equal to about half of average annual GDP over the period.'' In its Human Development Reports, the United Nations Development Program ranks countries by their values of the Human Development Index, [3] which is based on life expectancy at birth, as well as on the adult literacy rate and per capita GDP.
Since the 1950s, economists have recognized that, in the long run, the rate of economic growth is determined by (indeed equal to) the rate of technological progress. In neoclassical growth models developed by Nobel laureate Robert Solow, [4, 5] an economy will always converge towards a steady state rate of growth, which depends only on the rate of technological progress.
In early models of economic growth, the rate of technological progress was assumed to be given or exogenous: technological progress was regarded as 'manna from heaven'. Economists began to relax this clearly unrealistic assumption in the 1980s, by developing so-called 'endogenous growth models'. In Romer's [6] model, ''growth y is driven by technological change that arises from intentional [R&D] investment decisions made by profit-maximizing agents.'' 1 Jones [7] argued that ''technological progress [is] the ultimate driving force behind sustained economic growth'' and that ''technological progress is driven by research and development (R&D) in the advanced world.'' Technological change may be either disembodied or embodied. Suppose firm X invests in R&D, and that this investment results in a valuable discovery. If the technological advance is disembodied, consumers and other firms could benefit from the discovery without purchasing firm X's goods or services; they could benefit just by reading or hearing about the discovery. However, if the technological advance is embodied, consumers and other firms must purchase firm X's goods or services to benefit from its discovery. Solow [8] argued that, ''many if not most innovations need to be embodied in new kinds of durable equipment before they can be made effective. Improvements in technology affect output only to the extent that they are carried into practice either by net capital formation or by the replacement of oldfashioned equipment by the latest modelsy'' 2 Romer [6] also assumed that technological progress is embodied in new goods: ''new knowledge is translated into goods with practical value,'' and ''a firm incurs fixed design or research and development costs when it creates a new good. It recovers those costs by selling the new good for a price that is higher than its constant cost of production.'' Grossman and Helpman [9] argued that ''innovative goods are better than older products simply because they provide more 'product services' in relation to their cost of production.'' Bresnahan and Gordon [10] stated simply that ''new goods are at the heart of economic progress,'' and Bils [11] said that ''much of economic growth occurs through growth in quality as new models of consumer goods replace older, sometimes inferior, models.'' Hercowitz [12] concluded that '''embodiment' is the main transmission mechanism of technological progress to economic growth.'' When technological progress is embodied in new goods, the welfare of consumers (and the productivity of producers) depends on the vintage of the goods (or inputs) they purchase. In this context, 'vintage' refers to the year in which the good was first produced or sold. For example, the vintage of the drug simvastatin is 1993: that is the year it was approved by the US FDA and first sold. Solow was the first economist to develop a growth model that distinguished between vintages of (capital) goods. In Solow's model, [8] new capital is more productive than old capital because capital is produced based on known 1 Growth may also be driven by technological change arising from R&D investment by public organizations, e.g. the National Institutes of Health. 2 I hypothesize that innovations may be embodied in nondurable goods (e.g. drugs) and services as well as in durable equipment.
technology, and technology improves with time. [13] A number of econometric studies (Bahk and Gort, [14] Hulten, [15] Sakellaris and Wilson [16] ) have shown that manufacturing firms using latervintage equipment have higher productivity.
The extent to which the welfare of consumers or the productivity of producers depends on the vintage of the goods they purchase should depend on the research intensity of those goods. The greater the research intensity of the goods, the greater the impact of their vintage on consumer welfare and producer productivity. According to the National Science Foundation, [17] the pharmaceutical and medical devices industries are the most researchintensive industries in the economy.
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The objective of this paper was to investigate the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany and the effect of the vintage of chemotherapy treatments on age-adjusted cancer mortality rates of residents of France. 
Life Expectancy in Germany
The first element of X, ln_CT_SCANNERS, is an indicator of an important type of nonpharmaceutical medical innovation: diagnostic imaging innovation.
In principle, I would like to control for aspects of 'lifestyle' that affect health, such as the fraction of the population that smokes or is obese. Unfortunately, state-level time-series data on these variables are unavailable. Instead, three available measures of 'risky behaviour' are included: ln_AIDS, ln_DRUNK and ln_HARD.
It might also be desirable to control for health expenditure, although it is not clear whether states with larger increases in health expenditure should have larger or smaller increases in longevity, since people in worse health tend to use more healthcare. Unfortunately, data on health expenditure by state are not available. Instead, four measures of healthcare resources are included: ln_N_RX; ln_BEDS; ln_PHYSICIANS; and ln_PHARMACISTS.
In Data on the number of prescriptions, by drug, state and year (N_RX dst ) were obtained from the IMS Health National Prescription Analysis database, [18] which covers more than 99% of prescriptions reimbursed by German Sick Funds. It does not contain drugs used in a hospital, drugs completely paid out of pocket and drugs prescribed for members of private health insurance companies (approximately 10% of the German population, particularly high-income employees, self-employed people, the military and government officials). I was unable to obtain data on all drugs sold in 3 In 1997, ''medical substances and devices firms had by far the highest combined R&D intensity at 11.8 percent, y well above the 4.2-percent average for all 500 top 1997 R&D spenders combined. The information and electronics sector ranked second in intensity at 7.0 percent.'' [17] The pattern of 1997 R&D spending per employee is similar to that for R&D intensity, with medical substances and devices again the highest at $US29 095 per employee. Information and electronics is second at $US16 381. Combined, the top 500 R&D firms in 1997 spent $US10 457 per employee. The drug vintage measure POST1990% is constructed as follows: The drug vintage measure POST1995% is constructed as follows:
if the active ingredient of drug d was first approved by the FDA after 1995 = 0 otherwise a Age-adjusted death rates are weighted averages of age-specific death rates, where the weights represent a fixed population by age. They are used to compare relative mortality risk among groups and over time. An age-adjusted rate represents the rate that would have existed had the age-specific rates of the particular year prevailed in a population whose age distribution was the same as that of the fixed population.
b 'Vintage' refers to the year in which a good was first produced or sold (anywhere in the world). The US is the country in which many drugs are first launched. Also, it is difficult to obtain data on the date at which drugs were first launched in Germany. Data on the initial year of FDA approval of active ingredients (APP_YEAR d ) were obtained from the FDA's Drugs@FDA database. [19] I was able to determine the initial FDA approval year of products accounting for over 80% of the prescriptions in my sample. Table A2 in the SDC shows data on the top 25 drugs in my sample, ranked by the number of prescriptions during 2000-8. Figure 1 shows data on the vintage distribution of prescriptions consumed during the period 2000-8; it shows the percent of prescriptions consumed during 2000-8 that were for drugs approved after year t (t = 1940,...,2010). About 75% of prescriptions were for drugs approved after 1975, 50% were for drugs approved after 1986 and 25% were for drugs approved after 1993.
Age-Adjusted Mortality and Life Expectancy Data
The Information System of the Federal Health Monitoring [20] provides data on age-adjusted mortality rates, by state and year. It also provides time-series data on life expectancy in Germany as a whole, but not life expectancy by state. However, it provides data on age-specific mortality rates by state and year, from which life expectancy by state and year can be calculated.
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Data on life expectancy at birth during 2000-7 in selected states are shown in figure 2. The rate of increase of life expectancy varied across states and over time. In 2000, the life expectancy of Saarland's residents was higher than that of Mecklenburg-Vorpommern's residents; in 2007, it was slightly lower. In 2000, the life expectancy of Schleswig-Holstein residents was slightly higher than that of Berlin's residents; in 2007, it was lower.
Data on Other Variables
Data on population, the number of notifiable diseases per 100 000 individuals, 6 the number of new AIDS cases per 100 000 individuals, the number of CT scanners in hospitals and prevention or rehabilitation facilities, the number of people injured or killed in road traffic accidents under the influence of alcohol, and the number of users of hard drugs who came to police notice for the first time, by state and year, were also obtained from the Information System of the Federal Initial US FDA approval year 4 European Pharmaceutical Market Research Association (EphMRA) drug classification codes are shown in parentheses. The EphMRA classification is a modified version of the Anatomical Therapeutic Chemical (ATC) classification. See http://www.ephmra.org/classification/anatomical-classification.aspx. 5 Population-weighted averages of my state-level life expectancy estimates were verified as being very consistent with published estimates for Germany as a whole. 6 In the Federal Republic of Germany, health authorities must be informed about cases of certain notifiable diseases, which are listed in the Infection Protection Act. [21] Data on the incidence and prevalence of other diseases were not available.
Health Monitoring. [20] Data on GDP per person; the unemployment rate; and the number of hospital beds, physicians and pharmacists, by state and year, were obtained from Eurostat's regional statistics database [22] The complete dataset used for estimation is shown in table A3 in the SDC.
Empirical Results
Estimates of models of life expectancy and the age-adjusted mortality rate are presented in table III. I present estimates of six different models, since I used two alternative outcome measures and three alternative drug vintage measures.
In model 1, the dependent variable is life expectancy at birth, and the measure of prescription drug vintage is FDA_YEAR: the (weighted) mean FDA approval year of ingredients contained in prescriptions consumed. The coefficient on this variable is positive and highly significant (p = 0.004). This indicates that states with larger increases in drug vintage had larger increases in life expectancy.
The only other variable with a coefficient that is statistically significant at the 5% level is ln_NOTIF_DISEASES. As expected, an increase in the number of notifiable diseases per 100 000 individuals is associated with a decline in life expectancy. The coefficient on per capita income is insignificant (p = 0.202) and negative: longevity did not increase more in states with high income growth. Some previous investigators have also found evidence of a non-monotonic or even inverse relationship between income and longevity. Uchida et al. [23] found that ''for [Japanese] females high income was the factor significantly decreasing life expectancy at 65 years of age in 1980.'' Hupfeld [24] theoretically derived a non-monotonic relationship between income and longevity, based on heterogeneous elasticities of labour supply and otherwise standard assumptions. He analysed this relationship empirically for pensioners in the public pension system in Germany and found that ''the relationship between income and life expectancy is indeed non-monotonic for major sub-groups in the data.'' And Ruhm [25] argued that, ''although health is conventionally believed to deteriorate during macroeconomic downturns, the empirical evidence supporting this view is quite weak and comes from studies containing methodological shortcomings that are difficult to remedy. Recent research that better controls for many sources of omitted variables bias instead suggests that mortality decreases and physical health improves when the economy temporarily weakens. This partially reflects reductions in external sources of death, such as traffic fatalities and other 7 Data on educational attainment by state and year were not available.
accidents, but changes in lifestyles and health behaviors are also likely to play a role.'' The coefficient on ln_PHYSICIANS is negative and nearly significant (p = 0.067): states with larger increases in the number of physicians per 100 000 residents had smaller increases in life expectancy. As suggested in section 1.1, a larger quantity of health resources may be a response to unobserved negative health shocks. The coefficient on ln_HARD is positive and nearly significant (p = 0.086), which is surprising. However, the coefficient on FDA_ YEAR is quite insensitive to the inclusion of ln_PHYSICIANS and ln_HARD in the model. When these two variables are excluded, the coefficient on FDA_YEAR is larger and more significant: b = 0.258 (Z = 5.01, p < 0.001). Models 2 and 3 are similar to model 1 but, instead of FDA_YEAR, the measure of drug vintage is the fraction of prescriptions containing ingredients approved by the FDA after 1990 or 1995.
The estimates of these two models are qualitatively similar to the estimates of model 1. The coefficients on POST1990% and POST1995% are both positive and highly significant. Models 4-6 are similar to models 1-3, but in these models the dependent variable is the log of the ageadjusted mortality rate. The age-adjusted mortality rate and life expectancy at birth both depend on (are functions of) age-specific mortality rates, but they depend on them in different ways. Model 4 indicates that the age-adjusted mortality rate declined more in states with larger increases in the weighted mean FDA approval year of prescriptions. A 1-year increase in mean drug vintage was associated with a 1.8% decline in the age-adjusted mortality rate. The coefficient on ln_CT_SCANNERS is negative and significant in all three mortality-rate models. This is consistent with the hypothesis that longevity has been increased by diagnostic imaging innovation as well as by pharmaceutical innovation. 8   Table II . Sample statistics, by year, of variables included in the econometric model for Germany [18] [19] [20] 22] 8 Lichtenberg found that diagnostic imaging innovation as well as pharmaceutical innovation increased life expectancy in the US during the period 1991-2004. [26] The parameter estimates can be used to estimate how much of the 1. The parameter estimates can also be used to obtain a rough assessment of the overall cost effectiveness of pharmaceutical innovation. I define the incremental cost-effectiveness ratio (ICER) as follows: [27] per capita expenditure (in constant year 2000 values) on prescription drugs increased from h300 in 2000 to h364 in 2006. Assuming that this increase was entirely due to use of newer drugs, pharmaceutical innovation increased lifetime drug expenditure by h5187. The implied ICER is h11 597 (= h5187/ 0.45 years), or $US16 173 (at the current exchange rate of $US1.39 per h1) per life-year. This is a small fraction of leading economists' estimates of the value of (willingness to pay for) an additional year of life.
This rough assessment of the overall cost effectiveness of pharmaceutical innovation may be compared to evidence reported in the CostEffectiveness Analysis (CEA) Registry, [28] 9 a comprehensive database of cost-utility analyses on a wide variety of diseases and treatments. A search of the registry found (i) 545 pharmaceutical interventions that decreased cost and improved health (in which case the ICER was negative); (ii) 771 pharmaceutical interventions that increased cost and improved health at a cost of less than $US16 173 per QALY; and (iii) 1481 pharmaceutical interventions that increased cost and improved health at a cost of more than $US16 173 per QALY. Therefore, my estimate of the cost per life-year is not very far from the median of the estimates of cost per QALY reported in the CEA Registry.
However, evidence about the distribution of ICER estimates from clinical trials may be difficult to interpret, for several reasons. First, clinical trials of some important products may not provide ICER estimates. Johnson et al. [29] reported that ''end points other than survival [e.g. reduction in tumour size] were the approval basis for 68% (39 of 57) of oncology drug marketing applications granted regular approval and for all 14 applications granted accelerated approval from 1 January 1990, to 1 November 2002.'' Second, more cost-effective interventions may be used more frequently, so that the utilizationweighted mean ICER may be lower than the unweighted mean ICER. Third, the ICER of a drug is usually calculated using the price of the drug when it was launched, and the average price of a drug 20 years after it was launched 10 is generally much lower than its price when it was launched. Fourth, the ICER calculation may not account for reductions in other medical expenditure attributable to pharmaceutical innovation. For example, the UK National Institute for Health and Clinical Excellence (NICE) [30] acknowledged that its evaluation of the cost effectiveness of new drug treatments for rheumatoid arthritis did ''not include all potential benefits of these agents. For instance no account is taken of the possible reduction in the need for joint replacement surgery, hospitalization or needs for aids and appliances.'' Lichtenberg [31] has shown that these 'cost offsets' can be large, relative to the direct cost of the intervention.
Cancer Mortality in France
Two types of statistics are used to measure cancer mortality: survival rates and mortality rates. Survival rates are typically expressed as the proportion of patients alive at some point subsequent to the diagnosis of their cancer. For example, the observed 5-year survival rate is defined as shown in equation 2.
5-year survival rate ¼
no: of people diagnosed with cancer at time t alive at time t þ 5 no: of people diagnosed with cancer at time t ¼ 1 À no: of people diagnosed with cancer at time t dead at time t þ 5 no: of people diagnosed with cancer at time t ðEq: 2Þ Hence, the survival rate is based on a conditional (upon previous diagnosis) mortality rate. The second type of statistic is the unconditional cancer mortality rate: the number of deaths, with cancer as the underlying cause of death, occurring during a year per 100 000 population.
The outcome measure utilized here is the unconditional (age-adjusted) cancer mortality rate. Longitudinal, cancer-site-level data on conditional mortality (or survival) were not available during the period for which I have chemotherapy treatment data (2002-6), although they were available for earlier years.
11 Moreover, Welch et al. [33] argued that, ''while 5-year survival is a perfectly valid measure to compare cancer therapies in a randomized trial, comparisons of 5-year survival rates across time (or place) may be extremely misleading. If cancer patients in the past always had palpable tumors at the time of diagnosis while current cancer patients include those diagnosed with microscopic abnormalities, then 5-year survival would be expected to increase over time even if new screening and treatment strategies are ineffective.'' Consequently, the authors concluded that ''to avoid the problems introduced by changing patterns of diagnosis y progress against cancer [should] be assessed using [unconditional] population-based mortality rates.'' [33] 
Econometric Model
Models of the following form (equation 3) are estimated (see table V for how the variables are defined):
(Eq: 3Þ a s and d t represent cancer-site fixed effects and year fixed effects, respectively. A significant negative drug vintage coefficient (b) in equation 3 would indicate that cancer sites that had above-average increases in drug vintage had above-average reductions in the age-adjusted mortality rate. Equation 3 was estimated by WLS, weighting by the mean of each cancer site's mortality rate during the entire sample period ([1/T] P t AAMORT st ). The drug vintage measure LAUNCH_YEAR will be constructed as follows:
N_PATIENTS cst = the number of patients with cancer at site s who were treated with chemotherapy agent c in year t INTRO_YEAR c = the year in which chemotherapy agent c was first launched
The drug vintage measure POST1985% will be constructed as follows: The drug vintage measure POST1990% will be constructed as follows:
The Eurocare 3 and Eurocare 4 databases [32] provide data on survival rates of French cancer patients diagnosed during the following periods: 1983-5, 1986-8, 1989-91, 1992-4 and 1995-9. The estimation procedure will account for clustering of disturbances within cancer sites.
The drug vintage measure LAUNCH_YEAR was constructed as shown in table V. POST1990% was constructed in a similar fashion.
The only explanatory variable in equation 3 (aside from the cancer-site fixed effects and year fixed effects) is chemotherapy vintage. Cancer mortality rates are also likely to depend on other cancer-site-specific, time-varying variables, and these might be correlated with drug vintage. In particular, mortality rates are likely to depend on (i) incidence rates and (ii) non-pharmaceutical innovation. Unfortunately, data on cancer incidence and non-pharmaceutical innovation, by cancer site, were not available for France during the period covered by my chemotherapy data.
12 However, in a recent paper based on US cancer data during the period 1996-2006, Lichtenberg [35] found that, although pharmaceutical innovation, non-pharmaceutical innovation and incidence all had significant effects on cancer mortality rates, controlling for the latter two variables had virtually no effect on the pharmaceutical innovation coefficient.
Data and Descriptive Statistics

Pharmaceutical Data
Data on the number of patients with cancer at site s who were treated with chemotherapy agent c in year t (N_PATIENTS cst ) were obtained from the IMS Oncology Analyzer database. [36] 13 IMS collected data on the frequency with which 11 chemotherapy agents were administered to a sample of about 20 000 French cancer patients during the period 2002-6. The size of the sample increased over time from 2713 patients in 2002 to 5217 patients in 2006.
The 11 drugs (ranked by frequency of use), and the years in which they were launched, are shown in table A4 in the SDC. Table A5 in the SDC shows the number of sample patients during 2002-6, by cancer site.
The two cancer sites with the largest number of patients were breast and lung. The three chemotherapy agents most frequently used to treat each of the five cancer sites with the largest numbers of patients are shown in table A6 in the SDC.
Mortality Data
Data on age-adjusted 14 mortality rates, by cancer site, were obtained from the Centre for Epidemiology on Medical Causes of Death (Centre d'Epide´miologie sur les Causes me´dicales de De´ce`s) National Institute of Health and Medical Research (Institut National de la Santeé t de la Recherche Me´dicale). [37] The complete dataset used for estimation is shown in table A7 in the SDC.
Empirical Results
Estimates of chemotherapy vintage coefficients (b) from different versions of equation 3 are shown in table VI. The first three estimates are based on the full set of cancer sites. In model 1, the vintage measure is the (weighted) mean world launch year of chemotherapy treatments. The coefficient on LAUNCH_YEAR is negative and highly significant (p = 0.008). This indicates that cancer sites for which there were larger increases in chemotherapy vintage had larger reductions in the age-adjusted mortality rate. A 10-year increase in mean drug vintage is estimated to reduce the age-adjusted mortality rate by about 6%. Models 2 and 3 indicate that the change in the age-adjusted mortality rate was also inversely correlated with the other two measures of chemotherapy vintage (POST1985% and POST1990%). Model 2 implies that the mortality rate would be about 12% lower if only post-1985 drugs were used than it would be if only pre-1986 drugs were used.
As noted earlier, these are WLS estimates, where the weight is the mean of each cancer site's mortality rate during the entire sample period. As shown in figure 3 , the mortality rate for lung 12 Data on non-pharmaceutical innovation are not available for any period. According to the European Cancer Observatory, annual data on cancer incidence, by site, are only available during the period 1983-1997. [34] 13 If a patient was treated with n chemotherapy agents, that patient would be counted n times. 14 The age distribution of the French population in 2002 was used to obtain age-adjusted mortality rates.
cancer is far higher than it is for other types of cancer. Therefore, the estimates of models 1-3 give a great deal of weight to the lung cancer data. Models 4-6 are estimates based on the full set of cancer sites except lung cancer. All three drug vintage coefficients remain negative and highly significant when lung cancer is excluded from the sample. Excluding lung cancer increases the magnitude of b by about 25% in models 4 and 6 (compared with models 1 and 3), but reduces the magnitude of b by about 25% in model 5 (compared with model 2).
According to Eurostat, [38] the age-adjusted mortality rate from malignant neoplasms in There are two different data sources from which D was calculated. The first was the IMS Oncology Analyzer database. [36] As noted in section 2.2.1, this contains data on the use of 11 cancer drugs by about 4000 patients per year during the period 2002-6. The second data source is the Group for the Production and Elaboration of Statistics (GERS; Groupement pour l'Elaboration et la Re´alisation de Statistiques). [39] This source provides annual data on the use of all (106) cancer drugs by all cancer patients in France during the period 1998-2007.
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Table A8 in the SDC shows a comparison of chemotherapy vintage measures derived from the IMS Oncology Analyzer and GERS databases.
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The GERS estimates of the 2002-6 increase in mean vintage are about three times as large as the IMS estimates. For example, the GERS data imply that mean LAUNCH_YEAR increased by 5.5 years, while the IMS data imply that it increased by only 1.8 years.
Estimates of the decline in the age-adjusted mortality rate attributable to the 2002-6 increase in drug vintage based on both the IMS data and the GERS data are shown in table VII.
The estimates of D derived from the IMS Oncology Analyzer database imply that the increase in drug vintage reduced the age-adjusted cancer mortality rate by about 1% during 2002-6, which is about one-sixth of the total decline in the mortality rate. The estimates of D derived from the GERS database [12] imply that the increase in drug vintage reduced the age-adjusted cancer mortality rate by about 3% during 2002-6, which is about half of the total decline in the mortality rate.
Conclusions
Longevity increase is an important part of economic growth and development. In the long run, the rate of economic growth is determined by the rate of technological progress, which is generated by private and public R&D investment. Most technological progress is embodied in new goods. Therefore, the welfare of consumers (and the productivity of producers) depends on the vintage of the goods (or inputs) they purchase, especially when those goods are R&D intensive. The pharmaceutical and medical devices industries are the most R&D-intensive industries in the economy. 15 GERS provides data on the quantity of each drug, by year, but not by cancer site.
16 The GERS vintage measures are based on the year each drug was first commercialized in France, rather than the world launch year, which is not available for all drugs. For the 11 drugs for which both dates were available, there is generally a close correspondence between the two dates. For 8 of the 11 drugs, the year of commercialization in France was 0-2 years after the world launch year.
